Compare CVS Health Corp (CVS) vs Honest Company Inc (HNST) Price & Performance

CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.

The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.

HNST trades at $4.93, down 1.99% today, with a bearish technical outlook despite recent earnings beat. The company shows mixed fundamentals with negative net income margin (-3.56%) and ROE (-6.87%), though Q2 2026 EPS of $0.04 exceeded expectations. Revenue declined to $371M in 2025, but operating cash flow improved to $15.1M. Analyst consensus is mixed with 30% buy ratings and $5.30 price target.

The stock faces headwinds from profitability challenges and competitive pressures, though strategic exits show early signs of margin improvement. Upside potential exists if the company sustains recent operational improvements, but investors should weigh the high P/E ratio of 48.83 against ongoing net losses.